Combination of 8-methoxypsoralen and ultraviolet A inhibits smooth muscle proliferation in vitro and in vivo after angioplasty

Smooth muscle cell proliferation plays a major role in restenosis following angioplasty. We have studied the effects of ultraviolet A (UVA) activation of 8-methoxypsoralen (8-MOP) on cultured SMC as well as atherosclerotic rabbit femoral arteries following angioplasty. 8-MOP and UVA display synergistic proliferation inhibition of cultured SMC in a cell-cycle independent manner. At intermediate doses, a cytostatic effect was seen over a 28 day period following a single exposure. In conclusion, a combination of 8-MOP and UVA significantly lowered SMC proliferation and cellularity in cell culture as well as in the neointima and media after balloon-induced vascular injury in the atherosclerotic rabbit model. This approach of systemic administration and local activation is feasible and offers a potential therapy for restenosis.

[1]  M. Gallo,et al.  Psoralens potentiate ultraviolet light-induced inhibition of epidermal growth factor binding. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A E Profio,et al.  SKIN PHOTOSENSITIVITY: DURATION and INTENSITY FOLLOWING INTRAVENOUS HEMATOPORPHYRIN DERIVATES, HpD and DHE , 1987, Photochemistry and photobiology.

[3]  J. Laskin,et al.  Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment. , 1989, Molecular pharmacology.

[4]  E. Moustacchi,et al.  Molecular analysis by electron microscopy of the removal of psoralen-photoinduced DNA cross-links in normal and Fanconi's anemia fibroblasts. , 1990, Cancer research.

[5]  H. Fujita,et al.  DNA replication and cell-cycle progression of cultured mouse FM3a cells after treatment with 8-methoxypsoralen plus near UV-radiation. , 1982, Mutation research.

[6]  T J Flotte,et al.  Photodynamic therapy of arteries. A novel approach for treatment of experimental intimal hyperplasia. , 1992, Circulation.

[7]  L. Stolk,et al.  Biopharmaceutics, pharmacokinetics and pharmacology of psoralens. , 1988, General pharmacology.

[8]  T J Dougherty,et al.  Photodynamic therapy: status and potential. , 1989, Oncology.

[9]  N. Ratliff,et al.  Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. , 1985, Journal of the American College of Cardiology.

[10]  K. Kohn,et al.  DNA crosslinking and cell survival in human lymphoid cells treated with 8-methoxypsoralen and long wavelength ultraviolet radiation. , 1981, Mutation research.

[11]  D. Hathaway,et al.  Effects of thiol protease inhibitors on cell cycle and proliferation of vascular smooth muscle cells in culture. , 1993, Circulation research.

[12]  M. Nobuyoshi,et al.  Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.

[13]  J. Laskin,et al.  Characterization of a photoalkylated psoralen receptor in HeLa cells. , 1987, The Journal of biological chemistry.

[14]  J. Hearst,et al.  Dose-related effects of psoralen and ultraviolet light on the cell cycle of murine melanoma cells. , 1982, Cancer research.

[15]  E. Christophers,et al.  Photoinactivation and recovery in skin fibroblasts after formation of mono- and bifunctional adducts by furocoumarins-plus-UVA. , 1980, The Journal of investigative dermatology.

[16]  R. Wilensky,et al.  Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. , 1991, American Heart Journal.

[17]  A. A. Runovich,et al.  [Percutaneous transluminal coronary angioplasty]. , 1985, Grudnaia khirurgiia.

[18]  J. Laskin,et al.  Psoralen binding and inhibition of epidermal growth factor binding by psoralen/ultraviolet light (PUVA) in human epithelial cells. , 1991, Biochemical pharmacology.